Business Context and Reporting Period
Company: Nektar Therapeutics
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2005
Business Overview: Nektar is a biotechnology company focused on drug delivery technologies, including Advanced PEGylation, Pulmonary Technology, and Supercritical Fluid (SCF) Technology. The company generates revenue through collaborative research agreements, product sales (primarily PEG reagents), and commercialization readiness costs related to its partnership with Pfizer for the inhaled insulin product Exubera®.
Key Financial Metrics
| Metric (in thousands) | Q1 2005 | Q1 2004 (Restated) |
|---|---|---|
| Total Revenue | $28,494 | $25,831 |
| Net Loss | $(26,165) | $(40,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.31) | $(0.64) |
| Cash and Cash Equivalents | $47,516 | $32,064 |
| Short-term Investments | $353,787 | $386,676 |
| Total Current Assets | $428,847 | $454,539 |
| Total Current Liabilities | $51,491 | $55,653 |
| Long-term Debt (Convertible Notes) | $173,949 | $173,949 |
| Accumulated Deficit | $(743,286) | $(717,121) |
Liquidity: As of March 31, 2005, the company held approximately $401.3 million in cash, cash equivalents, and short-term investments. Management forecasts sufficient cash to meet net operating expense requirements through at least the end of 2006.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 10% to $28.5 million, driven by a 48% increase in product sales ($6.4 million vs. $4.3 million) and $2.6 million in new Exubera® commercialization readiness revenue. Contract research revenue declined 9% to $19.5 million, largely due to the absence of a $2.0 million termination fee received from Aventis-Behring in the prior year.
- Profitability Improvement: Net loss narrowed significantly to $26.2 million from $40.0 million in the prior year. This improvement was primarily due to a $13.3 million decrease in interest expense (following debt conversions in 2004) and the absence of a $9.3 million loss on debt extinguishment recorded in Q1 2004.
- Operating Expenses: Research and Development (R&D) expenses increased 12% to $34.9 million due to salary increases, a $1.4 million buy-out of royalty obligations, and increased validation testing for Exubera®. General and Administrative (G&A) expenses rose 33% to $9.1 million due to headcount increases and higher accounting fees.
- Restatement: Prior year figures for Q1 2004 were restated to reclassify $2.7 million from R&D to G&A and $0.3 million from G&A to interest expense. These changes did not affect net loss or cash position.
Guidance, Outlook, Risks, and Unusual Items
- Exubera® Status: In March 2005, Pfizer and Sanofi-Aventis announced the FDA accepted the New Drug Application (NDA) for Exubera®. Revenue from Pfizer represented 63% of total revenue for the quarter. The company faces significant risk if the collaboration is discontinued or if regulatory approval is delayed, which could impact contract revenue and trigger reimbursement obligations to contract manufacturers.
- Debt Maturity: The company has $173.9 million in convertible subordinated notes and debentures maturing in 2007. Management states it is unlikely to satisfy this obligation solely through operating cash flow and may need to raise additional capital or restructure debt.
- Accounting Changes: The company must adopt FAS 123R (Stock-Based Compensation) on January 1, 2006, which will require recognizing substantially more compensation expense, materially impacting future financial results.
- Unusual Items: The company recorded a $1.1 million loss on the termination of a capital lease for office space in San Carlos. Additionally, a securities class action lawsuit regarding Exubera® press releases was filed in September 2004; the motion for a lead plaintiff was withdrawn in April 2005.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2005, due to a material weakness in the financial statement close process identified in the prior year's 10-K.
Investor Verification Checklist
- Exubera® Regulatory Timeline: Verify the status of the FDA review process for Exubera® and the potential impact of any delays on the Pfizer collaboration revenue stream.
- Debt Refinancing Strategy: Assess the company's plan to repay or refinance the $173.9 million in convertible debt maturing in 2007, given the current lack of profitability.
- Internal Control Remediation: Review progress on remedying the material weakness in internal controls over financial reporting to ensure future reporting reliability.
- Customer Concentration: Monitor the dependency on Pfizer, which accounted for 63% of revenue, and the risks associated with the Sanofi-Aventis merger litigation.
- Impact of FAS 123R: Evaluate the projected increase in stock-based compensation expense upon the adoption of FAS 123R in 2006.